Drug Trial Radar · NCT07473167
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Aug 3, 2023
Primary completion
Feb 11, 2028
Study completion Mar 10, 2028
Sponsor
- Lead sponsor
- TICAROS Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
Conditions
- Relapsed Large B-cell Lymphoma
- Refractory Large B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- High-grade B-cell Lymphoma (HGBL)
- Transformed Follicular Lymphoma (TFL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interventions
TC011Drug
Anti-CD19 Chimeric Antigen Receptor T cell
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase1: Occurrence of Dose-Limiting Toxicities (DLTs)Time frame: Up to 4 weeks after TC011 infusion
- Phase1: Determination of Maximum Tolerated Dose (MTD)Time frame: up to 4weeks after TC011 infusion
- Phase1: Determination of Recommended Phase 2 Dose (RP2D)Time frame: Up to 12 weeks after TC011 infusion
- Phase 1: The number and incidence rate of treatment-emergent adverse events (TEAEs) as well as serious adverse events (SAEs) will be assessedTime frame: Up to 12 weeks after TC011 infusion
- Phase1: Number of participants with abnormal physical examination findingsTime frame: Baseline through Week 12
- Phase1: Number of participants with abnormal vital signsTime frame: Baseline through Week 12
- Phase1: Number of participants with abnormal ECG readingsTime frame: Baseline through Week 12
- Phase 1 : Number of participants with abnormal laboratory test resultsTime frame: Baseline through Week 12
- Phase 1 : Presence of Replication-Competent Lentivirus (RCL) Through Week 12Time frame: Baseline through Week 12
- Phase 2 : Objective Response Rate (ORR)Time frame: up to 24 weeks after TC011 infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.